No Data
No Data
BioAtla's Phase 2 Trial Of Ozuriftamab Vedotin Selected For Poster Presentation at 2025 ASCO
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $1
12 Health Care Stocks Moving In Monday's After-Market Session
H.C. Wainwright Maintains BioAtla(BCAB.US) With Hold Rating
Citizens Capital Markets Maintains Market Outperform on BioAtla, Lowers Price Target to $1